<DOC>
	<DOC>NCT00265382</DOC>
	<brief_summary>The purpose of this study is to assess the safety and tolerability of ziprasidone during long-term open-label administration in adolescents (ages 13-17) with schizophrenia.</brief_summary>
	<brief_title>Safety And Tolerability Of Ziprasidone In Adolescents With Schizophrenia</brief_title>
	<detailed_description>On March 24, 2009, Pfizer Inc. stopped late stage Geodon pediatric clinical trials in schizophrenia (A1281134 - placebo controlled; A1281135 - open label). As recommended by the DSMB, these studies were stopped due to lack of efficacy. No safety concerns were identified.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>Participation in doubleblind treatment study A1281134, meeting specific criteria of duration and safety Imminent risk of suicide or homicide, as judged by the site investigator Serious adverse event related to study medication in study A1281134 Significant prolongation of QT interval in study A1281134</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Adolescent Subjects</keyword>
</DOC>